Skip to main content
SpringerLink
Log in

Moderne Antidiabetika

Wie hoch ist der Patientennutzen wirklich?

Modern antihyperglycaemic agents — what is the patient benefit?

  • FORTBILDUNG_SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Neue orale Antidiabetika (OAD) haben die Behandlung des Diabetes mellitus Typ 2 in den letzten Jahren komplexer gemacht. Vor dem Start einer Insulintherapie gibt es nun immer mehr Kombinationsmöglichkeiten für eine zwei- und dreifach orale Therapie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559

    Article  CAS  PubMed  Google Scholar 

  2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.

    Article  PubMed  Google Scholar 

  3. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  PubMed  Google Scholar 

  4. Kostev K, Rathmann W. Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010). Prim Care Diabetes. 2013;7(3):229–33.

    Article  Google Scholar 

  5. Goldman J, White JR Jr. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. Ann Pharmacother. 2015;49(10):1153–61.

    Article  CAS  PubMed  Google Scholar 

  6. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 2014; 370: 1514–1523

    CAS  Google Scholar 

  8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865

  9. Eurich DT, Majumdar SR, McAlister FA et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345–2351

    Article  CAS  PubMed  Google Scholar 

  10. Eurich DT, Weir DL, Majumdar SR et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circulation Heart failure 2013; 6: 395–402

    Article  CAS  PubMed  Google Scholar 

  11. Rudofsky G, Rüssmann HJ, Siegmund T. [SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?]. Dtsch Med Wochenschr. 2013;138(22):1172–7.

    Article  CAS  PubMed  Google Scholar 

  12. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728–742

    Article  CAS  PubMed  Google Scholar 

  13. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–57.

    Article  PubMed  Google Scholar 

  14. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823–30.

    Article  CAS  PubMed  Google Scholar 

  15. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187–215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Deacon CF, Marx N. Potential cardiovascular effects of incretin-based therapies. Expert Rev Cardiovasc Ther 2012; 10: 337–351

    Article  CAS  PubMed  Google Scholar 

  17. Hocher B, Sharkovska Y, Mark M et al. The novel DPP-4 inhibitors linagliptin and BI 14 361 reduce infarct size after myocardial ischemia / reperfusion in rats. Int J Cardiol 2013; 167: 87–93

    Article  PubMed  Google Scholar 

  18. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 112–120

    Article  CAS  PubMed  Google Scholar 

  19. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

    Article  CAS  PubMed  Google Scholar 

  20. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.

    Article  CAS  PubMed  Google Scholar 

  21. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–42.

    Article  CAS  PubMed  Google Scholar 

  22. Udell JA, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee andInvestigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38(4):696–705.

    CAS  PubMed  Google Scholar 

  23. Ryder RE. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. Diabet Med. 2015;32(4):438–9.

    Article  CAS  PubMed  Google Scholar 

  24. Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract. 2012;98(2):175–86.

    Article  CAS  PubMed  Google Scholar 

  25. Erdmann E, Harding S, Lam H, Perez A. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab. 2016;18(3):266–73.

    Article  CAS  PubMed  Google Scholar 

  26. Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation. 2002;105(16):1928–33.

    Article  PubMed  Google Scholar 

  27. von Bibra H, Paulus P. Diastolische Dysfunktion. Echokardiographische Erfassung, Ätiologie und Therapieansätze. Kardiologe 2016 • 10:47–55

    Article  Google Scholar 

  28. von Bibra H, Siegmund T, Kingreen I, et al. Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study. Cardiovasc Diabetol. 2016;15(1):7.

    Article  Google Scholar 

  29. Heilmeyer P, von Bibra H. Diastolic heart failure treated by diet. Dtsch Med Wochenschr. 2016;141(2):121–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Städt. Klinikum München GmbH, Klinikum Bogenhausen, Klinik für Endokrinologie, Diabetologie und Angiologie, Englschalkinger Straße 77, D-81925, München, Deutschland

    Thorsten Siegmund

Authors
  1. Thorsten Siegmund
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Siegmund.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siegmund, T. Wie hoch ist der Patientennutzen wirklich?. MMW - Fortschritte der Medizin 158, 46–50 (2016). https://doi.org/10.1007/s15006-016-8061-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-016-8061-z

Keywords

Search

Navigation